54results about How to "Reduce fibrosis" patented technology

The invention discloses application of a siRNA composition in preparation of a medicine for treating liver diseases and the medicine. The siRNA composition at least comprises PCBP2-siRNA and PD-L1-siRNA. The invention discovers that PCBP2-siRNA and PD-L1-siRNA can effectively reduce type I collagen deposition in a mouse hepatic fibrosis model induced by CCL4 for the first time. The result shows that the two siRNAs both have a potential anti-fibrosis effect. And when the PCBP2-siRNA and the PD-L1-siRNA are used in a combined manner, the inhibition effect of the PCBP2-siRNA and the PD-L1-siRNA on the type I collagen deposition is more obvious than that of the PCBP2-siRNA which is independently used with any siRNA. The result shows that the liver fibrosis degree can be more effectively relieved through combined application of the two siRNAs.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses small protein UFD1s and application of the small protein UFD1s in prevention, treatment and diagnosis of non-alcoholic steatohepatitis, the small protein UFD1s provided by the invention has the effects of regulating energy metabolism and resisting cell stress, and the UFD1s can be used as an auxiliary diagnosis marker of the non-alcoholic steatohepatitis (NASH). Meanwhile, the deletion or low expression quantity of the UFD1s is related to the occurrence and development of the NASH, the UFD1s are expressed in vivo through the constructed expression substance and method, the effect of preventing and / or treating the NASH can be played, and a new thought is provided for preventing and / or treating the NASH.

The invention provides a skin care composition containing stem cell extract as well as a preparation method and application of the skin care composition, and belongs to the technical field of cosmetics. The method comprises the following steps: mixing and culturing the extracted urine-derived stem cells and pilose antler stem cells in a DMEM culture medium added with epidermal growth factors, cholera toxin, penicillin, streptomycin, transferrin, IL-2 and IL-15, then separating a culture solution to obtain mixed exosomes, mixed stem cells and extracellular matrixes, preparing the mixed stem cells into stem cell lipidosome, and preparing the stem cell lipidosome. Embedding the stem cell extract and the mixed exosome into titanium dioxide / silicon dioxide microspheres, adding into an extracellular matrix, and uniformly dispersing to obtain the skin care composition containing the stem cell extract. The skin care composition containing the stem cell extract prepared by the invention can obviously prolong the preservation period of stem cells and exosomes and improve the repair and improvement of the stem cells and the exosomes on skin, and the prepared composition has better effects of resisting aging, whitening, promoting skin elasticity, resisting wrinkles and the like, and has a wide application prospect.

The invention discloses a fibroblast exosome for repairing scars and a preparation method and application thereof, and relates to the technical field of biology, and the preparation method comprises the following steps: S1, taking fibroblasts, and carrying out adaptive culture on the fibroblasts in a complete culture medium for 24-30 hours; s2, after the adaptive culture is completed, replacing a new culture medium, culturing in a complete culture medium containing 10% of fetal calf serum until the fusion degree is 80%, carrying out digestion treatment by adopting 0.25% of pancreatin, centrifuging, collecting supernate, and carrying out ultracentrifugation extraction on the supernate to obtain a primary product of the fibroblast exosome; s3, carrying out transfection treatment on the primary product of the fibroblast exosome to obtain the fibroblast exosome for repairing scars; the prepared fiber-forming exosome can also influence the movement of epidermal and dermal cells by regulating the expression of related factors in a TGF-beta / Smad signal channel, and the regulating effect is mainly to promote scar-free healing of the skin, so that the generation of scars is reduced from the source.

The invention provides a composition with the effects of reducing uric acid and improving the renal function and a preparation method, application and a product of the composition, and belongs to the field of traditional Chinese medicine application. The composition is prepared from the following components: raw radix astragali, rhizoma smilacis glabrae, herba taxilli, radix salviae miltiorrhizae and rhizoma alismatis. According to the composition provided by the invention, the raw radix astragali, the rhizoma smilacis glabrae, the herba taxilli, the radix salviae miltiorrhizae and the rhizoma alismatis are combined for use, and the obtained composition can be used for treating hyperuricemia or related diseases thereof, and is remarkable in curative effect and small in toxic and side effects. The composition is used for post-treatment of hyperuricemia and is used for treating arthralgia and pain of joints and unfavorable flexion and extension. Meanwhile, the composition has a certain kidney protection effect and can reduce kidney inflammation and fibrosis.

The invention discloses application of CREB3L1 in diagnosis and treatment of systemic sclerosis, and belongs to the technical field of biological medicine. The invention discovers that CREB3L1 has the function of regulating and controlling fibrosis of skin and lung tissues of a patient with systemic sclerosis for the first time, and plays an important role in the progress of fibrosis of systemic sclerosis. The CREB3L1 can be used as a biomarker for diagnosis and auxiliary diagnosis of systemic sclerosis, and the CREB3L1 inhibitor can be used as an effective component for controlling and / or reversing fibrosis of systemic sclerosis, and has a good clinical application prospect. A new target is provided for diagnosis and treatment of systemic sclerosis, and a solid research foundation is laid for development of drugs for resisting systemic sclerosis fibrosis.

The invention relates to application of a UHRF1 inhibitor in preparation of a medicine for treating tissue fibrosis after spinal cord injury, and belongs to the technical field of biological medicine. The invention proves that the expression of UHRF1 can be increased due to spinal cord injury; compared with mice of a false operation group, the mice of which the UHRF1 is specifically knocked down in the fibroblasts have the advantages that fibrosis caused by spinal cord injury is obviously reduced, nerve regeneration is promoted, and the motor function is obviously improved. In the aspect of mechanism, the knock-down of UHRF1 leads to the reduction of the number of proteins combined on a PPM1A gene promoter, the weakening of the transcription inhibition effect and the promotion of the expression of the PPM1A gene, while the PPM1A can inhibit the phosphorylation of Smad2 / 3 and inhibit the conduction of a TGF-beta1 / Smads pathway, thereby inhibiting tissue fibrosis.

The invention relates to the technical field of biological medicine, and discloses PROTAC capable of degrading PRRX2 protein in cells and application of the PROTAC, and the PROTAC is formed by connecting a target protein ligand and an E3 ubiquitin ligase ligand through an azide-alkyne cycloaddition reaction; the structure of the target protein ligand is as shown in a formula 1: # imgabs0 #. The chimera for targeting protein hydrolysis can be specifically recognized with a PRRX2 transcription factor, so that the pulmonary arterial hypertension is reduced.

The present invention belongs to the field of biological medicine technology, and relates to a new application of daptomycin, specifically the application of daptomycin in the preparation of drugs for treating or preventing chronic pancreatitis. Daptomycin can inhibit macrophage M2 polarization, reduce pancreatic fibrosis caused by chronic pancreatitis, and reduce pancreatic tissue changes caused by chronic pancreatitis. The present invention may provide an effective prodrug for the prevention and treatment of chronic pancreatitis.

The invention discloses application of triflorin or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating heart aging and / or myocardial injury. The invention provides a new strategy and a candidate substance for developing medicines, health-care products or functional foods for preventing, delaying and / or treating heart aging and / or myocardial injury, maintaining heart health and reducing the risk of aging-related cardiovascular diseases.

The invention discloses application of a miR-497a-5p inhibitor in preparation of a medicine for preventing or treating liver diseases, and the miR-497a-5p gene can be used as a regulation target or a regulation marker in the medicine for preventing or treating the liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The invention proves that the miR-497a-5p inhibitor can be used for preventing or treating the liver diseases on an animal model of the liver related diseases.

The application relates to the field of biological medicine, and provides application of hydrochloric acid dinedarong in preparation of a medicine for treating non-alcoholic fatty liver disease and cholestatic liver disease. The application discloses a new medical use of hydrochloric acid dinedarong, which can significantly reduce liver injury, lipid deposition in the liver and liver fibrosis caused by high-fat high-fructose high-cholesterol diet, and can reduce liver injury and liver fibrosis caused by cholestasis. Therefore, the hydrochloric acid dinedarong has the effect of treating non-alcoholic fatty liver disease and cholestatic liver disease.

The invention provides application of SB225002 in preparation of a medicine for treating myocardial infarction and a composition for treating myocardial infarction, and relates to the technical field of medicines. The main mechanism of the SB225002 for treating myocardial infarction is inflammation inhibition and myocardial repair and regeneration promotion, and the SB225002 is used for regulating and controlling a group of specific mononuclear cells so as to achieve the effect of inhibiting multiple inflammation signal channels, including reduction of the expression quantity of channel-related genes and the like; meanwhile, the SB225002 can also promote proliferation of myocardial cells and angiogenesis and reduce the fibrosis degree of heart tissue after infarction, so that repair and regeneration of the heart after infarction are promoted; the SB225002 enables inflammation and repair to reach a certain balance, so that a better treatment effect is achieved.

The invention relates to the technical field of biology, and provides an NCLX gene modified bone marrow mesenchymal stem cell as well as a preparation method and application thereof, and the bone marrow mesenchymal stem cell contains an NCLX gene or a nucleotide sequence with homology and equal function in the nucleotide sequence of the NCLX gene. The NCLX gene modified bone marrow mesenchymal stem cells have strong tolerance to hypoxia, and have strong resistance to active oxygen. Animal experiments also prove that mice in an experimental group obviously improve lung tissue alveolar collapse and inflammatory cell infiltration conditions and reduce fibrosis of lung tissues, and the NCLX gene modified bone marrow mesenchymal stem cells have the potential of being developed into drugs for treating radiation-induced lung injury. And a new treatment scheme is provided for prevention and treatment application in radiation-induced lung injury.

The invention belongs to the technical field of biology, and mainly relates to a preparation method and application of N1, N10-bisdihydrodicaffeoyl spermidine. According to the invention, the spermidine component N1, N10-bisdihydrodicaffeoyl spermidine of lycium ruthenicum is obtained through water extraction, macroporous resin separation and preparative liquid chromatography purification. The purity of the N1, N10-bisdihydrodicaffeoyl spermidine obtained by the preparation method disclosed by the invention is high and reaches 98% or above. The prepared N1, N10-bisdihydrodicaffeoyl spermidine can directly activate the activity of G6PD, improve the NADPH (nicotinamide adenine dinucleotide phosphate) level, improve the heart function in a dose-dependent manner, and reduce the formation and fibrosis of scar tissues. Under a high dose (20mg / kg / day), the protection effect of the N1, N10-bisdihydrodicaffeoyl spermidine on myocardial deficiency-reperfusion injury is equivalent to that of metoprolol tartrate (MTA), and the N1, N10-bisdihydrodicaffeoyl spermidine can be used for preparing a product for preventing and treating ischemia-reperfusion injury.

The application discloses application of an Hsc70 inhibitor in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines for treating ischemic heart disease. The application proves through pharmacodynamics and molecular mechanism research that a specific small-molecule inhibitor of Hsc70 can be used for preparing a medicine for treating ischemic heart disease or myocardial regeneration. The specific small-molecule inhibitor of Hsc70 directly combines with an ATP enzyme domain of Hsc70, blocks the interaction between Hsc70 and mitochondrial fusion protein 2 (Mfn2), further reduces the contact between mitochondria and lipid droplets under pathological conditions, and then releases cell cycle inhibition and up-regulates CDK1 and MCM5 expression. The medicine can significantly reduce the infarction area after myocardial infarction, reduce fibrosis, improve the systolic and diastolic functions of the heart, and can protect myocardial cells from suffering from hypoxia / reoxygenation-induced systolic dysfunction, thereby providing a new medicine selection for clinically treating myocardial infarction and heart failure.

The present invention belongs to the field of medicine, and discloses an application of sinomenine in the preparation of a drug for preventing / inhibiting the progression of scarring of the filtration tract after glaucoma filtration surgery, wherein the drug is a local ocular administration type drug. The present invention firstly discovers that sinomenine has a certain therapeutic effect on scarring of the filtration tract after glaucoma filtration surgery, and inhibits excessive fibrosis of the subconjunctiva and sclera surface after glaucoma filtration surgery through the anti-fibrosis effect of sinomenine, which can effectively delay and inhibit postoperative filtration tract fibrosis, prolong the survival of the filtration tract, and provide a new treatment idea for the disease.

The invention provides application of exosomes from senescence mesenchymal stem cells overexpressing miR-423-3p in preparation of myocardial infarction protection drugs, and the miR-423-3p which is obviously differentially expressed between exosomes from young and senescence bone marrow mesenchymal stem cells (hBMSCs) is screened out, so that the miR-423-3p can be used for preparing the myocardial infarction protection drugs, and the miR-423-3p can be used for preparing the myocardial infarction protection drugs. The protection capability of the exosome for the heart after myocardial infarction is effectively improved in a manner of overexpressing miR-423-3p from the aging mesenchymal stem cell-derived exosome, the heart function is improved, the apoptosis of hypoxia myocardial cells is inhibited, and the treatment effect of the aging stem cell-derived exosome for treating myocardial infarction is improved.

The present invention discloses the use of Atf3-siRNA in the preparation of a drug for treating liver fibrosis caused by schistosomiasis japonicum, and relates to the field of biomedicine technology. The present invention discloses the use of Atf3-siRNA in the preparation of a drug for treating liver fibrosis caused by schistosomiasis japonicum, and the base sequence of Atf3-siRNA is 5'-CTGAGATTCGCCATCCAGAAT-3'. The results of the embodiments of the present invention show that compared with the siNC group, the degree of liver fibrosis in mice in the siAtf3 group is relatively alleviated, and there are still many gray-white worm egg nodules on the surface of the liver, which are reddish-brown in color and relatively soft in texture. Compared with the siNC group, the range of granulomas in the liver of mice in the siAtf3 group was significantly reduced, and the blue collagen was significantly reduced. In summary, ATF3 knockdown significantly alleviated the liver fibrosis lesions caused by Schistosoma japonicum infection.

The invention belongs to the technical field of medicines, and particularly relates to application of diacerein and derivatives thereof in preparation of medicines for inhibiting fibrosis and promoting local tissue regeneration. The medicine for inhibiting fibrosis and / or promoting local tissue regeneration is prepared from diacerein and the derivative thereof, so that fibrosis induced by a biological material, the immune cell infiltration degree and tissue calcification can be resisted, the wound regeneration healing speed can be increased, and meanwhile, the effects of resisting fibrosis and promoting local tissue regeneration are achieved.

The invention belongs to the technical field of new application of medicines, and provides application of ginseng epoxy alkynol in preparation of medicines for treating myocardial infarction. The ginseng epoxy alkynol can protect the process of lesion and myocardial infarction caused by left anterior descending branch ligation of the heart to a certain extent, reduce the degree of myocardial fibrosis, reduce the infarction area, relieve ventricular wall tumors, effectively reduce the degree of myocardial infarction and relieve myocardial ischemia after myocardial infarction. The compound has a wide application prospect in treatment of myocardial infarction, especially acute myocardial infarction.

This invention discloses a vitamin A-functionalized polyphenol-phospholipid complex, its preparation method, and its applications, belonging to the field of pharmaceutical formulation and nanodelivery technology. The phospholipid complex comprises a polyphenol drug, a phospholipid material, and a vitamin A phospholipid ligand. The vitamin A phospholipid ligand is formed by vitamin A or its derivatives and a phospholipid derivative containing amino or other reactive groups. The phospholipid complex forms a phospholipid composite structure through non-covalent interactions between the polyphenol drug and the phospholipid material, and the vitamin A phospholipid ligand is inserted into or assembled into the surface or interior of the phospholipid composite structure. Animal experiments show that this phospholipid complex can reduce serum transaminase levels and alleviate the degree of liver fibrosis, and has good blood compatibility and tissue safety. This invention provides an industrially achievable targeted nano-formulation solution for early intervention in liver fibrosis, with promising application prospects.

A triple agonist peptide having activity on each of a GLP-1, a glucagon, and a GIP receptor is provided. Also described are triple agonist analogs having one or more biotin moieties and / or fatty acid moieties conjugated thereto to improve bioavailability and pharmacokinetics. Compositions and formulations of these triple agonist peptides are particularly suitable for treating, ameliorating and / or preventing one or more metabolic diseases, such as obesity, diabetes or non-alcoholic fatty liver disease. Compositions and methods of use thereof for the treatment, amelioration and / or prevention of one or more neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), are also described.

The present invention relates to the use of Spexin active polypeptide in the preparation of drugs for preventing and treating ventricular remodeling, and belongs to the technical field of drugs for preventing and treating ventricular remodeling. The present invention provides a new drug use of Spexin active polypeptide, that is, the use of Spexin active polypeptide in the preparation of drugs for preventing and treating ventricular remodeling, and the amino acid sequence of the Spexin active polypeptide is NWTPQAMLYLKGAQ. Animal experimental results confirm that Spexin active polypeptide can significantly inhibit abnormal myocardial energy metabolism during ventricular remodeling, and can reduce the occurrence of structural remodeling such as myocardial hypertrophy, fibrosis and myocardial cell apoptosis, thereby improving cardiac function. The present invention applies Spexin active polypeptide to the preparation of drugs for preventing and treating ventricular remodeling, develops its new clinical use, and is expected to be developed into a new generation of safe and effective new drugs for preventing and treating heart diseases.

The invention relates to application of a chemokine ligand 19 inhibitor capable of treating systemic sclerosis, and belongs to the technical field of biological medicine. The invention provides application of a chemokine ligand 19 inhibitor in preparation of a medicine for preventing and / or treating systemic sclerosis. Researches show that the chemotactic factor ligand 19 can promote immune cell infiltration in the skin by recruiting CCR7 + T cells in peripheral blood, aggravate skin fibrosis, and also can promote the immune cell infiltration in the skin by recruiting CCR7 + T cells in the peripheral blood. The anti-chemokine ligand 19 monoclonal antibody has a remarkable treatment effect on systemic sclerosis (specifically, the anti-chemokine ligand 19 monoclonal antibody can relieve infiltration of immune cells in skin of a systemic sclerosis modeling mouse and relieve the fibrosis degree of the skin of the systemic sclerosis modeling mouse by inhibiting expression of the chemokine ligand 19 in fibroblasts). Therefore, the chemokine ligand 19 can be used as a new target for preventing and treating the systemic sclerosis, and has a great application prospect in preparation of medicines for preventing and / or treating the systemic sclerosis.

The invention relates to the technical field of biological medicine, in particular to application of a ferroptosis inhibitor in preparation of a medicine for preventing and treating intraocular hypertension. Research finds that the ferroptosis inhibitor can effectively slow down fibrosis of trabecular meshwork cells caused by SiO, and evidence and thought are provided for treating intraocular hypertension caused by SiO filling.

The present invention belongs to the field of traditional Chinese medicine, and in particular to a Chinese medicine composition for treating myocardial infarction and its application. The Chinese medicine composition for treating myocardial infarction of the present invention comprises, by weight, 10-20 parts of coptis root, 9-15 parts of pinellia tuber, 15-30 parts of whole trichosanthes root, 5-15 parts of cinnamon twig, 9-30 parts of allium macrostemon, 5-15 parts of immature bitter orange, 5-30 parts of raw astragalus, 6-15 parts of zedoaria, and 15-30 parts of salvia miltiorrhiza. Experiments on acute myocardial infarction mouse model show that the Chinese medicine composition of the present invention can improve the inflammatory microenvironment after myocardial infarction, inhibit ventricular negative remodeling, and improve cardiac function, indicating that the Chinese medicine composition of the present invention has a good therapeutic effect on myocardial infarction.

The invention discloses application of formyl phloroglucinol mixed-source terpene derivatives or pharmaceutically acceptable salts thereof in preparation of drugs for preventing and treating liver lipid metabolism abnormality related diseases, and relates to terpenes. The liver lipid metabolism disorder related diseases are obesity, hyperlipidemia, atherosclerosis (AS), metabolism related fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM). The formyl phloroglucinol mixed-source terpenoid derivative is found to be capable of reducing anabolism of liver fatty acid and cholesterol for the first time, so that liver lipid deposition is reduced, dyslipidemia is improved, and the formyl phloroglucinol mixed-source terpenoid derivative can be used for preventing and treating liver lipid metabolism disorder related diseases.

The invention relates to hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological hydrogel materials. The hydrogel comprises a prednisolone sodium phosphate hydrogel P-Gel skeleton and gold nanoparticles PCAu, wherein the gold nanoparticles PCAu are uniformly loaded on the P-Gel skeleton and are coated by procyanidine. According to the preparation method, a three-dimensional cross-linked network skeleton of PSP hydrogel P-Gel is self-assembled and constructed by utilizing ion coordination and hydrogen-bond interaction of prednisolone sodium phosphate PSP under the action of Ca < 2 + >, and the hydrogel PCAu-coated P-Gel is formed by uniformly loading gold nanoparticles PCAu which are green synthesized from procyanidine PC and have stable surfaces. The hydrogel can promote rapid repair of spinal cord injury and relieve far-end muscle atrophy and fibrosis; and meanwhile, the injectable self-healing hydrogel has the engineering advantages of injectability, self-healing and the like, and shows good clinical transformation potential.